The Biopharma R&D sector is facing a productivity paradox. Despite record investments in AI and high-throughput technologies, clinical success rates continue to decline. At the heart of this crisis lies the Epistemic Gap: a fundamental disconnect between theoretical laboratory models and the complex biological reality of human patients.
Jobst Landgrebe Consulting provides a dual-engine strategy to restore R&D efficiency: By integrating Biomathematical Rigour with Human-Centric Validation (Organoids), we help research leaders move beyond speculative “black-box” models. Our “Smart Selection” approach identifies “false positive” targets early, ensuring that only assets with the highest Probability of Success (PoS) proceed to the clinic.
From Methodological Audits to solving technical deadlocks in “undruggable” targets, we provide modular interventions designed to increase capital efficiency. Whether through interim management, talent scouting, or scientific due diligence, our focus remains constant: closing the gap between theory and human therapeutic success.